NYMOX PHARMACEUTICAL CORPORATION Key Management Personnel Compensation Share-based Payment
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) reported Key Management Personnel Compensation Share-based Payment of $142.32 thousand for the 3-month period ending 2021-09-30, per its 6-K filed 2021-11-12.
Discontinued › Notes › Compensation Related Costs
ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment · last filed 2021-11-12
- NYMOX PHARMACEUTICAL CORPORATION key management personnel compensation share-based payment for the quarter ending 2021-09-30 was $142.32K, a 56.10% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION key management personnel compensation share-based payment for the quarter ending 2021-06-30 was $184.83K, a 50.74% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION key management personnel compensation share-based payment for the quarter ending 2021-03-31 was $229.19K, a 46.56% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION key management personnel compensation share-based payment for the quarter ending 2020-09-30 was $324.15K.
| Period end | Key Management Personnel Compensation Share-based Payment 3 month | Key Management Personnel Compensation Share-based Payment 6 month | Key Management Personnel Compensation Share-based Payment 9 month | Key Management Personnel Compensation Share-based Payment 12 month |
|---|---|---|---|---|
| 2021-09-30 | $142.32K 6-K · filed 2021-11-12 | $327.14K derived: sum of 2 quarters · filed 2021-11-12 | $556.33K 6-K · filed 2021-11-12 | |
| 2021-06-30 | $184.83K 6-K · filed 2021-08-13 | $414.01K 6-K · filed 2021-08-13 | ||
| 2021-03-31 | $229.19K 6-K · filed 2021-05-14 | |||
| 2020-09-30 | $324.15K 6-K · filed 2021-11-12 | $699.33K derived: sum of 2 quarters · filed 2021-11-12 | $1.13M 6-K · filed 2021-11-12 | |
| 2020-06-30 | $375.17K 6-K · filed 2021-08-13 | $804.05K 6-K · filed 2021-08-13 | ||
| 2020-03-31 | $428.88K 6-K · filed 2021-05-14 | |||
| 2018-12-31 | $819.36K derived: 20-F 12 month − 6-K 9 month · filed 2019-03-29 | $1.96M derived: sum of 2 quarters · filed 2019-03-29 | $2.88M derived: sum of 3 quarters · filed 2019-03-29 | $3.88M 20-F · filed 2019-03-29 |
| 2018-09-30 | $1.14M 6-K · filed 2018-11-13 | $2.06M derived: sum of 2 quarters · filed 2018-11-13 | $3.06M 6-K · filed 2018-11-13 | $1.01B derived: sum of 4 quarters · filed 2019-03-29 |
| 2018-06-30 | $913.96K 6-K · filed 2018-08-13 | $1.92M 6-K · filed 2018-08-13 | $1.01B derived: sum of 3 quarters · filed 2019-03-29 | $1.01B derived: sum of 4 quarters · filed 2019-03-29 |
| 2018-03-31 | $1.01B 6-K · filed 2018-05-15 | $1.01B derived: sum of 2 quarters · filed 2019-03-29 | $1.01B derived: sum of 3 quarters · filed 2019-03-29 | $1.01B derived: sum of 4 quarters · filed 2019-03-29 |
| 2017-12-31 | $919.38K derived: 20-F 12 month − 6-K 9 month · filed 2019-03-29 | $3.23M derived: sum of 2 quarters · filed 2019-03-29 | $4.58M derived: sum of 3 quarters · filed 2019-03-29 | $6.07M 20-F · filed 2019-03-29 |
| 2017-09-30 | $2.31M 6-K · filed 2018-11-13 | $3.66M derived: sum of 2 quarters · filed 2018-11-13 | $5.15M 6-K · filed 2018-11-13 | |
| 2017-06-30 | $1.35M 6-K · filed 2018-08-13 | $2.85M 6-K · filed 2018-08-13 | ||
| 2017-03-31 | $1.50B 6-K · filed 2018-05-15 | |||
| 2016-12-31 | $9.07M 20-F · filed 2019-03-29 |